DARATUMUMAB SHOWS REMARKABLE BENEFIT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE POLLUX STUDY

| REFRACTORY MULTIPLE MYELOMA IN THE POLLUX STUDY | |
|---|--|
| | |
| Dr Meletios A Dimopoulos (Abstract LB2238): | |

IMMUNOTHERAPY DELIVERED BY BLINATUMOMAB IMPROVES SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKAEMIA PATIENTS (TOWERStudy)

Dr Max S Topp (Abstract S149):

Comment Prof. Dr. med. Markus Manz, Klinikdirektor,

Klinik für Hämatologie, UniversitätsSpital Zürich:

THE ROOT OF EVIL: PRE-LEUKEMIC CLONES THAT SURVIVE CHEMOTHERAPY ARE LINKED TO A HIGHER RISK OF LEUKEMIA RECURRENCE

Dr Klaus Metzeler (<u>Abstract S146</u>):

STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL

| Dr Johan Richter (Abstract S145): |
|--|
| I |
| MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH NOACS OR VKAS IN REAL-LIFE: CLINICAL PRESENTATION, MANAGEMENT AND OUTCOME |
| Dr Laura Franco (Abstract S139): |
| I |
| RESTORING EFFECTIVE ANTI-TUMOR RESPONSE IN HODGKIN LYMPHOMA WITH NIVOLUMAB |
| Dr Anas Younes (Abstract S793): |

EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES

Dr Jeffrey Jones (Abstract S429):



A NEW FORM OF INHERITED THROMBOCYTOPENIA (ETV6-RELATED THROMBOCYTOPENIA, ETV6- RT): NEVER JUDGE A BOOK BY ITS COVER!

Dr Federica Melazzini (Abstract S148):